Puberty Blocker Guidelines for Gender Dysphoria in Minors: An Update on Italy’s Joint Initiative

Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

In response to the growing concern over gender dysphoria in minors, the Ministry of Health and the Ministry of Family have announced a joint initiative to develop new guidelines for the use of triptorelin, a puberty blocking drug. This collaborative effort is being led by Ministers Orazio Schillaci and Eugenia Roccella, with the aim of creating evidence-based guidelines that prioritize the best practices for this complex issue.

The two ministries have conducted extensive investigative work on gender dysphoria and the use of blockers, including a hearing with scientific societies involved in the issue of gender dysphoria in adolescents. They have also requested that the National Bioethics Committee reevaluate the use of triptorelin in cases of gender dysphoria in minors, and are currently conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria. Additionally, they have requested a report from AIFA on the therapeutic indications for the drug.

This proactive approach to addressing gender dysphoria in minors represents a significant step forward in ensuring that patients receive evidence-based care that prioritizes their best interests. As experts continue their work to develop new specific guidelines for this important issue, we can expect updates on this initiative in the coming days.

Leave a Reply